+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dart NeuroScience LLC - logo

Dart NeuroScience LLC develops technologies and therapeutics to maximize cognitive vitality throughout life. Its research program includes developing methods of gene discovery, gene network informatics, drug discovery, and chemistry to identify small molecules for use as therapies for various brain disorders. DNS currently has three drugs in clinical studies and drug programs for 10 additional innovative targets in earlier stages of discovery. The company was founded in 2008 and is based in San Diego, California.

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • July 2022
  • 57 Pages
  • Global
From
Parkinson's Disease Market: Pipeline Review, Developer Landscape and Competitive Insights - Product Thumbnail Image

Parkinson's Disease Market: Pipeline Review, Developer Landscape and Competitive Insights

  • Report
  • May 2018
  • 204 Pages
  • Global
From
GABAA Modulators - Pipeline Insight, 2024 - Product Thumbnail Image

GABAA Modulators - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Depressive Disorders (Major Depression, Bipolar Disorder, Postpartum Depression, Treatment-Resistant Depression, and Others): Pipeline Review, Developer Landscape and Competitive Insights, 2019 - Product Thumbnail Image

Depressive Disorders (Major Depression, Bipolar Disorder, Postpartum Depression, Treatment-Resistant Depression, and Others): Pipeline Review, Developer Landscape and Competitive Insights, 2019

  • Report
  • April 2019
  • 208 Pages
  • Global
From
Glycine Transporter Type-1 (Glyt-1) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Glycine Transporter Type-1 (Glyt-1) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - Product Thumbnail Image

Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • Report
  • November 2022
  • 50 Pages
  • Global
From
  • 6 Results (Page 1 of 1)
Loading Indicator